Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2025; 31(45): 112336
Published online Dec 7, 2025. doi: 10.3748/wjg.v31.i45.112336
Published online Dec 7, 2025. doi: 10.3748/wjg.v31.i45.112336
Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma
Takuya Watanabe, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, Niigata 9502002, Japan
Author contributions: Watanabe T solely contributed to this manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takuya Watanabe, MD, PhD, Director, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, 1-2-21 Aoyama, Nishi-ku, Niigata 9502002, Japan. nabetaku@dia-net.ne.jp
Received: July 28, 2025
Revised: October 2, 2025
Accepted: October 31, 2025
Published online: December 7, 2025
Processing time: 130 Days and 1.1 Hours
Revised: October 2, 2025
Accepted: October 31, 2025
Published online: December 7, 2025
Processing time: 130 Days and 1.1 Hours
Core Tip
Core Tip: Chimeric antigen receptor (CAR)-T therapy, particularly lisocabtagene maraleucel (liso-cel), offers a promising option for patients with relapsed or refractory and relapsed follicular lymphoma (FL), demonstrating high response rates and a favorable safety profile in the TRANSCEND FL trial. Compared to other CAR-T products, liso-cel shows advantages in toxicity, logistics, and feasibility. This editorial emphasizes its relevance for gastrointestinal FL, a subgroup often underrepresented in studies, and calls for broader inclusion and real-world validation to optimize CAR-T use across FL subtypes.